(Q35718553)

9 August 2017

1 reference

title

Neuroprotective actions of coenzyme Q10 in Parkinson's disease (English)

1 reference

9 August 2017

0 references

1 reference

Sharma S

1

1 reference

9 August 2017

Kheradpezhou M

2

1 reference

9 August 2017

Shavali S

3

1 reference

9 August 2017

El Refaey H

4

1 reference

9 August 2017

Eken J

5

1 reference

9 August 2017

Hagen C

6

1 reference

9 August 2017

Ebadi M

7

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

9 August 2017

published in

Methods in Enzymology

1 reference

9 August 2017

volume

382

1 reference

9 August 2017

page(s)

488-509

1 reference

Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Mitochondrial therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Peroxynitrite formed by mitochondrial NO synthase promotes mitochondrial Ca2+ release.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Mitochondrial nitric oxide synthase, oxidative stress and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Neurodegenerative disorders: the role of peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Coenzyme Q10 as a possible treatment for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Nitric oxide in neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Endogenous nitric oxide synthesis: biological functions and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Distribution of coenzyme Q homologues in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Biochemistry of Nitric Oxide and Its Redox-Activated Forms

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

ALS, SOD and peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Inhibition of mitochondrial electron transport by peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Nitric oxide in health and disease of the nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

The antioxidant properties of zinc and metallothionein

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Changes of metallothionein i + ii proteins in the brain after l-methyl-4-phenylpyridinium administration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

MPTP decreases MT-I mRNA in mouse striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

(-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

An endogenous dopaminergic neurotoxin: implication for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Nitric oxide enhances MPP(+)-induced hydroxyl radical generation via depolarization activated nitric oxide synthase in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Role of nitric oxide in the regulation of monoaminergic neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

NOS knockouts and neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Peroxynitrite‐Mediated Inhibition of DOPA Synthesis in PC12 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

MPP(+) increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Olfactory dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Where does parkinson disease pathology begin in the brain?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Olfactory impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Oxidative stress and antioxidant therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0076-6879%2804%2982027-5

7 January 2021

10.1016/S0076-6879(04)82027-5

Identifiers

DOI

1 reference

9 August 2017

1 reference